Skip to main content

Table 1 Effect of δ-T3 and α-TOS treatments on cell viability of TUBO and SKBr3 mammary carcinoma cells

From: Why tocotrienols work better: insights into the in vitro anti-cancer mechanism of vitamin E

VE form

Breast cancer cells

IC50 [μM] (time of treatments)

δ-T3

TUBOb

>100 (6 h)

35 (18 h)

30 (24 h)

SKBr3c

45.6 (24 h)a

31.5 (48 h)a

α-TOS

TUBOb

>100 (6 h)

55 (18 h)

55 (24 h)

SKBr3c

>100 (24 h)a

68.4 (48 h)a

  1. The cells were treated for the times shown in parentheses with increasing concentrations of the test compounds between 0.5 and 100 mM
  2. IC50 data obtained from TUBO cell experiments have been presented in (Viola et al. 2010) (manuscript in preparation). In these cells, viability was assessed by MTT test as shown in (Mazzini et al. 2010)
  3. a(Pierpaoli et al. 2010)
  4. b TUBO mammary lobular carcinoma cells derived from BALB-neu T mice
  5. c SKBr3 Her-2/neu positive human mammary carcinoma cells (HTB-30; American Type Culture Collection (ATCC), Manassas, VA)
Back to article page

Genes & Nutrition

ISSN: 1865-3499

Contact us